Skip to main content
. 2016 Oct 4;7(43):69231–69242. doi: 10.18632/oncotarget.12470

Figure 5. ROS in mitochondria of control and FGF23-treated PV cardiomyocytes.

Figure 5

A. An example and B. average data of mitochondrial levels of ROS in control (n = 8) and FGF23 (1 ng/mL)-treated PV cardiomyocytes (n = 8) before and after ranolazine (10 μM, RAN) administration. * p < 0.05.